Daily Cardiology Research Analysis
Analyzed 172 papers and selected 3 impactful papers.
Summary
Three impactful cardiology studies stood out: a JACC analysis shows the 2025 ASE diastolic function algorithm misses many invasively proven HFpEF cases; a JAMA Cardiology cohort demonstrates that combining prediabetes status with hs-cTnI/NT‑proBNP markedly improves HF risk stratification in hypertension; and a Heart systematic review finds no clear benefit of fluid restriction in heart failure and signals harm via thirst distress.
Research Themes
- Diagnostic algorithm validation and recalibration in HFpEF
- Biomarker-integrated risk stratification for heart failure prevention
- De-implementation of low-value care (fluid restriction in HF)
Selected Articles
1. Echocardiographic Diastolic Function Grading in HFpEF: Testing the Updated 2025 ASE Criteria.
In invasively confirmed HFpEF, the 2025 ASE diastolic grading algorithm frequently labeled patients as normal or Grade 1 despite elevated filling pressures, and stress criteria detected only a small fraction of cases. The algorithm poorly discriminated HFpEF from noncardiac dyspnea, underscoring the need to interpret diastolic grades within HFpEF-specific diagnostic frameworks.
Impact: This study challenges a newly proposed echocardiographic standard and demonstrates substantial under-detection of HFpEF, with direct implications for diagnostic pathways.
Clinical Implications: Do not rely on the 2025 ASE diastolic grading alone to exclude HFpEF. Combine diastolic indices with clinical pretest probability and, when needed, invasive hemodynamics or HFpEF-specific algorithms.
Key Findings
- Among 756 ambulatory HFpEF patients, 67.6% were labeled normal or Grade 1 despite >60% having resting PAWP ≥15 mm Hg.
- ASE-recommended stress criteria detected only 9.5% of Grade 1 HFpEF during hemodynamic exercise testing (false-negative rate 90.5%).
- Poor discrimination of HFpEF vs. noncardiac dyspnea (AUC 0.61); patients labeled normal/Grade 1 had markedly elevated risk of death/HF hospitalization (HR 5.37).
Methodological Strengths
- Use of invasive hemodynamic gold standard and stress testing in a prospective cohort
- External validation and comparison with existing HFpEF algorithms
Limitations
- Observational diagnostic evaluation without randomized design
- Generalizability may vary across laboratories and echocardiographic acquisition protocols
Future Directions: Develop HFpEF-specific echocardiographic algorithms calibrated to invasive hemodynamics and validate in multi-center, prospective diagnostic accuracy studies.
BACKGROUND: Echocardiographic grading of left ventricular diastolic function is recommended to guide diagnostic evaluation of heart failure with preserved ejection fraction (HFpEF). A new algorithm for diastolic function interpretation has been proposed, but it has not yet been systematically evaluated in HFpEF. OBJECTIVES: The purpose of this study was to determine the false-negative rate of the 2025 American Society of Echocardiography (ASE) algorithm among invasively confirmed ambulatory HFpEF, assess temporal changes in diastolic grades between decompensated and recompensated hospitalized HFpEF, and, secondarily, to compare diagnostic discrimination with existing HFpEF algorithms and prognostic associations. METHODS: Echocardiography was performed in 2 HFpEF cohorts: 1) ambulatory, compensated patients undergoing invasive hemodynamic exercise testing as part of a prospective cohort study, with an external validation cohort; and 2) hospitalized/decompensated patients both acutely and following recompensation. For secondary analyses, we included noncardiac dyspnea controls and compared performance with existing algorithms. RESULTS: In the ambulatory/compensated HFpEF cohort, 248 of 756 (32.8%) were graded normal, 263 of 756 (34.8%) had Grade 1 diastolic dysfunction, 219 of 756 (30.0%) had Grades 2 to 3, and 26 of 756 (3.4%) were indeterminate. Among those labeled normal or Grade 1, >60% had resting pulmonary artery wedge pressure ≥15 mm Hg at catheterization. In decompensated HFpEF, 22 of 88 (25.0%) showed normal or Grade 1, and this proportion increased to 45 of 88 (51.1%) after recompensation. In HFpEF with Grade 1 undergoing simultaneous hemodynamic exercise testing with stress imaging, only 11 of 116 (9.5%) met the ASE-recommended stress criteria, resulting in a 90.5% false-negative rate. Similar findings were observed in the external validation cohort. The 2025 ASE algorithm poorly discriminated HFpEF from noncardiac dyspnea (AUC: 0.61). Patients with HFpEF labeled as normal or Grade 1 had 5-fold higher risk for all-cause death or heart failure hospitalization compared with controls (HR: 5.37; 95% CI: 1.27-22.6). CONCLUSIONS: Among patients with invasively proven HFpEF, the 2025 ASE algorithm frequently assigns normal or low diastolic grades, and the recommended stress criteria detect only a minority of cases. Although echocardiography remains essential to guide HFpEF evaluation, current algorithms proposed have inadequate sensitivity. Diastolic function grades must be interpreted in the context of pretest probability and HFpEF-specific, evidence-based frameworks, rather than used in isolation to exclude disease.
2. Prediabetes, Subclinical Myocardial Injury or Stress, and Heart Failure Risk for Adults With Hypertension.
In hypertensive adults, prediabetes combined with elevated hs‑cTnI (injury) or NT‑proBNP (stress) markedly increases incident HF risk, with similar signals when biomarkers rise ≥25% over 12 months. Integrating glycemic status with cardiac biomarkers refines HF risk stratification.
Impact: Provides pragmatic, biomarker-driven HF risk stratification in a large, well-characterized cohort, actionable for prevention in hypertension.
Clinical Implications: Screen hypertensive patients—especially those with prediabetes—with hs‑cTnI and NT‑proBNP to identify high HF risk and prioritize aggressive risk modification and follow-up.
Key Findings
- Prediabetes + elevated hs‑cTnI conferred HR 4.20 (95% CI 2.31–7.63) for incident HF versus normoglycemia without injury.
- Prediabetes + elevated NT‑proBNP conferred HR 5.20 (95% CI 2.52–10.70) for incident HF.
- A ≥25% 12‑month increase in hs‑cTnI or NT‑proBNP with prediabetes was associated with higher HF risk (hs‑cTnI HR 3.05; NT‑proBNP HR 2.39).
Methodological Strengths
- Prospective cohort within a randomized trial framework (SPRINT) with adjudicated HF outcomes
- Both cross-sectional baseline and longitudinal biomarker change analyses
Limitations
- Post hoc analysis; potential residual confounding despite adjustment
- SPRINT exclusion criteria may limit generalizability to broader hypertensive populations
Future Directions: Test biomarker-guided prevention strategies (e.g., intensified blood pressure and metabolic management) in randomized trials among biomarker-positive prediabetic hypertensive patients.
IMPORTANCE: It is unclear whether and the extent to which subclinical myocardial injury or stress coexisting with prediabetes is associated with the risk of heart failure (HF). OBJECTIVE: To evaluate the joint associations of prediabetes and subclinical myocardial injury or stress with incident HF risk. DESIGN, SETTING, AND PARTICIPANTS: This post hoc prospective cohort study analyzed data from the Systolic Blood Pressure Intervention Trial (SPRINT). Two analytic samples were used: (1) adults with hypertension without diabetes or prior HF for the baseline biomarkers analysis and (2) participants with biomarker measurements at both baseline and 12 months for the longitudinal biomarkers' change. Prediabetes was defined as a fasting plasma glucose level of 100 to 125 mg/dL. Subclinical myocardial injury was defined as a high-sensitivity cardiac troponin I (hs-cTnI) level of 6 ng/L or higher in men and 4 ng/L or higher in women and subclinical myocardial stress defined as an N-terminal pro-B-type natriuretic peptide (NT-proBNP) level of 125 pg/mL or higher. A 25% or greater increase in any biomarker concentration from baseline to 12 months defined longitudinal change. Data were analyzed between January 1 and May 31, 2025. MAIN OUTCOMES AND MEASURES: The primary outcome was adjudicated incident HF. Cox proportional hazards models were used to estimate hazard ratios (HRs) for HF across joint categories of prediabetes and biomarker elevation. RESULTS: Of 8234 participants (mean [SD] age, 68 [9] years; 37.1% women), 3271 (39.7%) had prediabetes, 2942 (35.7%) had subclinical myocardial injury, and 3593 (43.6%) had subclinical myocardial stress. Over a median follow-up of 3.2 years (IQR, 2.8-3.8 years), 122 participants developed HF. Compared with normoglycemia and no myocardial injury, those with both prediabetes and injury had the highest HF risk (HR, 4.20; 95% CI, 2.31-7.63); similar findings were observed for myocardial stress (HR, 5.20; 95% CI, 2.52-10.70). In the longitudinal analysis (median follow-up, 2.3 years [IQR, 1.9-2-8 years]), 7449 participants with both prediabetes and a 25% or greater increase in hs-cTnI or NT-proBNP level had the highest risk of HF (for hs-cTnI: HR, 3.05; 95% CI, 1.58-5.88; for NT-proBNP: HR, 2.39; 95% CI, 1.28-4.46). CONCLUSIONS AND RELEVANCE: These findings suggest that among adults with hypertension, prediabetes in combination with subclinical myocardial injury or stress is associated with a significantly elevated risk for HF. These findings support the integration of glycemic status and cardiac biomarkers profiling to improve HF risk stratification and guide prevention.
3. Fluid restriction in patients with heart failure: a systematic review.
Across four RCTs involving 682 HF patients, fluid restriction did not reduce mortality or HF hospitalizations and increased thirst distress, with no consistent QoL benefit. Current evidence does not support routine fluid restriction in HF care.
Impact: Challenges a long-standing non-pharmacological recommendation in HF and supports de-implementation of routine fluid restriction.
Clinical Implications: Avoid blanket fluid restriction in HF. Individualize advice focusing on congestion management, sodium intake, and diuretic titration; address thirst distress proactively.
Key Findings
- No RCT showed reductions in mortality or HF hospitalization with fluid restriction versus comparators.
- Thirst distress was consistently higher with fluid restriction across trials.
- No significant differences in NYHA class or (NT‑pro)BNP levels; QoL findings were inconsistent.
Methodological Strengths
- Systematic, multi-database search with predefined outcomes and protocol registration (CRD42022292319)
- Focus on randomized controlled trials across inpatient and outpatient settings
Limitations
- Only four RCTs with heterogeneity; no meta-analysis possible
- Most trials had high risk of bias and limited power
Future Directions: Conduct adequately powered, pragmatic RCTs targeting symptomatic subgroups (e.g., severe hyponatremia, advanced congestion) to test tailored fluid guidance vs. usual care and measure patient-centered outcomes (thirst, QoL).
BACKGROUND: Fluid restriction is a commonly prescribed non-pharmacological intervention in the management of heart failure (HF). However, data on its efficacy and safety are scarce. Recent randomised clinical trial (RCT) data prompt reassessment of the available evidence. METHODS: CINAHL, EMBASE, PubMed and the Cochrane Library were searched up to 1 May 2025. RCTs were included if adults with HF were randomised to fluid restriction in comparison to a liberal or unrestricted intake, less strict restriction or usual care. Outcomes of interest were mortality, HF hospitalisation, quality of life (QoL), thirst distress, New York Heart Association (NYHA) class and N-terminal pro-Brain Natriuretic Peptide (CRD42022292319). No meta-analysis was performed due to high heterogeneity of the included trials. RESULTS: In total, four RCTs were included, comprising 682 randomised inpatient, recently discharged and stable outpatient patients (ranging from 46 to 504 patients per trial). Only one study had a low risk of bias. None of the four trials found a significant difference in mortality or HF hospitalisations. For QoL, the results are contradictory, but overall, there is no clear benefit for fluid restriction, but it resulted in more thirst distress. No significant differences in NYHA class or (NT-pro)BNP were observed. CONCLUSION: Studies on fluid restriction in patients with HF are scarce, and most of the available studies are at high risk of bias. Although power is lacking, there is no evidence indicating that fluid restriction affects mortality or HF hospitalisations, but there is a signal of harm in terms of thirst distress. Taken together, the current evidence does not support the routine use of fluid restriction in patients with HF.